Tribute to John Wilkinson
John Wilkinson author of ‘Face Cancer’ book
This is our tribute to John Wilkinson, author of the Face Cancer book sharing his experiences of sinus cancer and supporting various charities. Diagnosed with an aggressive, large and rare form of sinus cancer in 2017, an avid cancer advocate and author of ‘Face Cancer’, John Wilkinson has lost his battle with cancer.
It is with great sadness that we learned recently that our friend John Wilkinson passed away on Christmas Day 2019. Our thoughts are very much with his family.
Utterly committed to helping others
John was utterly committed to using his diagnosis as a tool to help others and spread the word about head and neck cancer. He wrote the Face Cancer book and perhaps most importantly, talked about it in the press and took it on tour, talking to hundreds of people about what it is like to be diagnosed with head and neck cancer, debunking myths, explaining signs and symptoms. Showing by example that it is possible to achieve incredible things despite his diagnosis.
And John kept this up even while receiving palliative care; sharing his experiences and supporting charities through it all. We’re so grateful that Oracle Head & Neck Cancer UK was one of the many charities he supported through the proceeds of his “Face Cancer” Book.
John’s wife Jane is committed to continuing his good charity work and keeping the ‘Face Cancer Fund’ alive, and has an event planned with John’s previous employer HSBC. We at Oracle Head & Neck Cancer UK are very honoured to have received donations from his funeral which we will use to support our pioneering research.
Thank you, John for everything. Rest easy.
Cancer Care: Why Mental Health Support Must Be Part of Every Cancer Journey
Oracle Head & Neck Cancer UK is proud to support the Daily Express Cancer Care campaign, a powerful series that shines a light on the often unseen emotional toll of cancer – and the urgent need for better psychological support for everyone affected. The campaign published over the past three weeks featured voices from across…
Ground-breaking blood test shows promise for early detection of head & neck and other hard-to-screen cancers
A new large-scale trial has found that the blood-based screening test known as Galleri test can detect more than 50 types of cancer – including cancers of the head and neck, which currently have no routine screening programme – and may significantly boost early diagnosis. The trial showed that, when used alongside existing screening methods,…
2 Minutes to Save Your Life: Oracle Launches HeadNeckCheck Campaign for Make Sense Week
This Make Sense Week (15-20 September), the European-wide head and neck cancer awareness initiative, Oracle Head & Neck Cancer UK, is championing both prevention and early detection – recognising that stopping cancer before it starts is just as vital as catching it early. Two Ways to Fight Cancer This Week Prevention Today: Head and neck…
Leadership update
After four successful years as CEO, Tamara Kahn has transformed Oracle into a respected national voice for head and neck cancer patients. She established a national presence, created a four-pillar RACE strategy (Research, Awareness, Collaboration and Patient/Community Engagement) and built strong policy influence. With these foundations now firmly in place, Tamara will transition from her…
Finding Light in Adversity: Seven inspiring stories through head and neck cancer
A new collection of patient stories from Oracle Head and Neck Cancer UK reveals how individuals facing head and neck cancer have discovered unexpected sources of strength, purpose and even joy during their treatment and recovery. The seven contributors share remarkably similar themes despite their unique journeys. Almost all emphasise the power of maintaining a…
NHS to fast-track patients with head and neck cancer into cancer vaccine trial
Patients with advanced head and neck cancers in England will be fast-tracked into a trial of a new cancer vaccine, as the NHS expands its world-leading trial ‘match-making’ service. The investigational cancer vaccine uses mRNA technology to help the immune system recognise and kill cancer cells containing human papillomavirus proteins. More than 100 patients with advanced head…
World Head and Neck Cancer Awareness Day 2025: The HPV Vaccine Could Save Your Life
27th July 2025 This World Head and Neck Cancer Awareness Day, Oracle Head and Neck Cancer UK has a simple but urgent message: HPV vaccination saves lives. With HPV-related head and neck cancers having doubled in the past 20 years, the charity is using today to remind the public that these devastating cancers are preventable…
Data from the National Disease Registration Service on HPV associated and HPV independent oropharyngeal squamous cell carcinoma
The Get Data Out Programme from the National Disease Registration Service (NDRS), part of NHS England, has published statistics on incidence, routes to diagnosis and treatment for patients diagnosed with oropharyngeal cancer in England by human papillomavirus (HPV) status. To our knowledge this is the first time data on oropharyngeal cancer by HPV status has…
Join Us for an Evening of Research, Impact, and Conversation
Research & Impact EveningDate: Monday 28th April 2025Time: 6:00 PM – 8:30 PMVenue: Skyline, Tower Suites, 100 Minories, London EC3N 1JY A Celebration of Research Join us for a meaningful and action-focused evening where we’ll be diving into some of the big conversations around head and neck cancer – especially those linked to HPV (human…
What the Rare Cancers Bill Means for Head & Neck Cancer
14 March marked a crucial moment for research into rare cancers, as the Rare Cancers Bill took another significant step toward becoming law! Dr. Scott Arthur, a Labour MP, introduced this legislation in Parliament to drive much-needed research into cancers affecting fewer than 1 in 2000 people in the UK – including many types of…
Help Beat Head and Neck Cancer
Oracle Head & Neck Cancer UK is a registered charity in England and Wales (1142037), and in Scotland (SC052790).
Registered as a company limited by guarantee in England and Wales (7125497). Registered address: 80 Coombe Road, New Malden KT3 4QS.